Why are the FDA and USPTO Ignoring Requests for Info on I-MAK?
Briefly

The question of drug pricing raises many complicated questions, and policy must be based on a true and accurate vision of the numerous complex underlying facts... Although patents are an easy target, they are not the problem.
Numerous inquiries have been made by my staff in an attempt to determine when you would complete and provide the assessment and analysis to our offices... Unfortunately, neither agency has provided a firm commitment regarding a transmittal date.
Read at IPWatchdog.com | Patents & Intellectual Property Law
[
add
]
[
|
|
]